Novo Nordisk's CEO Has a Comeback Plan

from The Journal. · host The Wall Street Journal & Spotify Studios

When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night. Further Listening: - Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out? - Trillion Dollar Shot Sign up for WSJ’s free What’s News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published May 26, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Novo Nordisk's CEO Has a Comeback Plan

0:00 21:59

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Journal.?

This episode is 21 minutes long.

When was this The Journal. episode published?

This episode was published on May 26, 2026.

Can I download this The Journal. episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!